Richie E R, Monié H J, Trentin J J, Taub R N
Transplantation. 1975 Feb;19(2):115-20.
51Cr-labeled parental strain spleen cells were pretreated in vitro with antithymocyte globulin (ATG) or Fab fragments of ATG before i.v. injection into F1 recipients. Recipients were killed at various intervals after injection and their organs were assayed for radioactivity in order to determine the in vivo distribution pattern of pretreated cells. 51Cr spleen cells pretreated with ATG were almost totally prevented from migrating to spleens, lymph nodes, bone marrow, Peyer's patches, lungs, and peripheral blood of recipients. Pretreatment of 51Cr spleen cells with noncytotoxic Fab of ATG also inhibited localization to these organs and tissues; however, the inhibition was not as complete as that of ATG-treated cells. Localization of Fab-treated 51Cr spleen cells to recipient nodes was inhibited to a greater extent than was localization to recipient spleens. There was no significant difference in the extent of inhibition of ATG-treated 51Cr spleen cells to recipient nodes and spleen. Organ counts from recipients killed at various intervals after injection of Fab-treated 51Cr spleen cells showed that Fab-treated cells do not recover their recirculating potential in vivo.
将51Cr标记的亲代菌株脾细胞在静脉注射到F1受体之前,先在体外用抗胸腺细胞球蛋白(ATG)或ATG的Fab片段进行预处理。在注射后的不同时间间隔处死受体,并检测其器官的放射性,以确定预处理细胞在体内的分布模式。用ATG预处理的51Cr脾细胞几乎完全被阻止迁移到受体的脾脏、淋巴结、骨髓、派伊尔结、肺和外周血中。用ATG的无细胞毒性Fab预处理51Cr脾细胞也抑制了其在这些器官和组织中的定位;然而,这种抑制并不像用ATG处理的细胞那样完全。与受体脾脏相比,Fab处理的51Cr脾细胞在受体淋巴结中的定位受到的抑制程度更大。用ATG处理的51Cr脾细胞对受体淋巴结和脾脏的抑制程度没有显著差异。在注射Fab处理的51Cr脾细胞后的不同时间间隔处死受体后进行的器官计数显示,Fab处理的细胞在体内无法恢复其再循环潜力。